Treatment of smoking in smokers with chronic obstructive pulmonary disease;Tratamiento del tabaquismo en fumadores con enfermedad pulmonar obstructiva crónica

Archivos de Bronconeumologia

Volumn 49, Issue 8, 2013, Pages 354-363

  Jiménez Ruiz, Carlos A ^a   Riesco Miranda, Juan Antonio ^b   Altet Gómez, Neus ^c   Lorza Blasco, Jose Javier ^d   Signes Costa Miñana, Jaime ^e   Solano Reina, Segismundo ^f   de Granda Orive, Jose Ignacio ^g   Ramos Pinedo, Angela ^h   Martinez Muñiz, Manuel A ⁱ   Barrueco Ferrero, Miguel ^j  

^a Comunidad de Madrid ^*  (Spain)

^b HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^c CAP Drassanes   (Spain)

^d Universidad Pública de Navarra   (Spain)

^e HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g Department of Neurology   (Spain)

^h HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

ⁱ HOSPITAL SAN AGUSTÍN   (Spain)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

Bupropion; Chronic obstructive pulmonary disease; Nicotine replacement therapy; Smoking; Treatment; Varenicline

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; HUMAN; SMOKING HABIT; COGNITIVE BEHAVIORAL THERAPY; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; HEALTH BEHAVIOR; MOTIVATION; NICOTINE REPLACEMENT THERAPY; REWARD; SELF CONCEPT; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE;

AMFEBUTAMONE; VARENICLINE;

EID: 84881027212     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2013.06.001     Document Type: Article

References (51)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 [consultado 1 Ene 2012]. Disponible en: http://www.goldcopd.org/.
2. Sørheim I., Johannesse A., Gulsvik A., Bakke P.S., Silverman E.K., DeMeo D.L. Gender differences in COPD: Are women more susceptible to smoking effects than men?. Thorax 2010, 65:480-485.
3. Jiménez-Ruiz C.A., Masa J., Miravitlles M., Gabriel R., Viejo J.L., Villasante C., et al. Smoking characteristics: Differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001, 119:1365-1370.
4. Shahab L., Jarvis M.J., Britton J., West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006, 61:1043-1047.
5. Guía de práctica clínica para el diagnóstico y tratamiento del pacientes con EPOC, Guía española de la EPOC. Arch Bronconeumol 2012, 48(Supl 1):2-58. Grupo de trabajo de GesEPOC.
6. Pozo F., Alvarez C.J., Castro A., Melero C., Capelastegui A., Esteban C., et al. Auditoría clínica de los pacientes hospitalizados por exacerbación de EPOC en España (estudio AUDIPOC): método y organización del trabajo. Arch Bronconeumol 2010, 46:349-357.
7. Clark K.D., Wardrobe-Wong N., Eliot J.J., Priece T., Lindends T., Larstrom B. Cigarette smoke inhalation and lung damage in smokers volunteers. Eur Respir J 1998, 12:395-399.
8. Hilberink S.R., Jacobs J.E., Schlösser M., Grol R.P., de Vries H. Characteristics of patients with COPD in three motivational stages related to smoking cessation. Patient Educ Couns 2006, 61:449-457.
9. Ng T.P., Niti M., Tan W.C., Cao Z., Ong K.C., Eng P. Depressive symptoms and chronic obstructive pulmonary disease: Effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007, 167:60-67.
10. Wagena E.J., Kant I.J., Huibers M.J.H., van Amelsvoort L.G., Swaen G.M., Wouters E.F., et al. Psychological distress and depressed mood in employees with asthma, chronic bronchitis or emphysema: A population-based observational study on prevalence and the relationship with smoking cigarettes. Eur J Epidemiol 2004, 19:147-153.
11. Anthonisen N.R., Connett J.E., Kiley J.P., Altose M.D., Bailey W., Buist S., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. JAMA 1994, 272:1497-1505.
12. Dautzenberg B., Nides M., Kienzler J.L., Callens A. Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2mg nicotine bitartrate lozenges. BMC Clin Pharmacol 2007, 8:11.
13. Tønnesen P., Mikkelsen K.L. Routine smoking cessation with 4 nicotine regiments in a lung clinic. Eur Respir J 2000, 16:714-722.
14. Tønnesen P., Mikkelsen K., Bremann L. Nurse-conducted smoking cessation in patients with COPD, using nicotine sublingual tablets and behavioral support. Chest 2006, 130:334-342.
15. Strassmann R., Bausch B., Spaar A., Kleijnen J., Braendli O., Puhan M.A. Smoking cessation interventions in COPD: A network meta-analysis of randomised trials. Eur Respir J 2009, 34:634-640.
16. Tashkin D.P., Kanner R., Bailey W., Buist S., Anderson P., Nides M., et al. Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo-controlled, randomised trial. Lancet 2001, 357:1571-1575.
17. Wagena E.J., Knispchild P.G., Huibers M.J., Wouters E.F., van Schayk C.P. Efficacy of bupropión and nortriptyline for smoking cessation among people at risk for or with COPD. Arch Intern Med 2005, 165:2286-2292.
18. Tashkin D.P., Rennard S., Hays J.T., Lawrence D., Marton J.P., Lee T.C. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial. Chest 2011, 139:591-599.
19. Jiménez-Ruiz C.A., Ramos Pinedo A., Cicero Guerrero A., Mayayo M., Cristobal M., López G. Characterisitics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res 2012, 14:1035-1039.
20. Sundblad B.M., Larsson K., Nathell L. High rates of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine Tob Res 2008, 10:883-890.
21. Hoogendoorn M., Feenstra T.L., Hoogenveen R.T., Rutten-van Mölken M.P.M.H. Long term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 2010, 65:711-718.
22. Jiménez Ruiz C.A., Fagerström K.O. Diagnóstico y tratamiento del tabaquismo. Consideraciones generales. Tratado de tabaquismo 2011, 289-294. Aula Médica, Madrid. 3.a ed. C.A. Jiménez Ruiz, K.O. Fagerström (Eds.).
23. Heatherton T.F., Kozlowsky L.T., Frecker R.C., Baker T., Whisler W., Fagerström K.O. The Fagerström test for nicotine dependence: A revision of the Fagerström tolerance questionnaire. Br J Addict 1991, 86:1119-1127.
24. John U., Meyer C., Schumann A., Hapke U., Rumpf H.J., Adam C., et al. A short form of the Fagerström Test for Nicotine Dependence and the Heaviness of Smoking Index in two adult population samples. Addict Behav 2004, 29:1207-1212.
25. Pomerleau O.F., Fagerstrom K.O., Marks J., Tate J.C., Pomerleau C.S. Development and validation of a self-rating scale for positive-and negative-reinforcement smoking: The Michigan Nicotine Reinforcement Questionnaire. Nicotine Tob Res 2003, 5:711-718.
26. Jarvis J., Russell M.A.H. Expired air CO: A simple breath of tobacco smoke intake. Br Med J 1980, 281:484-485.
27. Prochazka J., DiClemente C. Stages and process of self-change of smoking: Towards an integrative model of change. J Clin Psychol 1983, 3:390-395.
28. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz N, Curry S, et al. Treating Tobacco Use and Dependence: 2008 update. Clinical practice guideline, Rockville MD: US. Deparment of Health and Human Service. May 2008. Traducción al español: Jiménez Ruiz CA, Jaén CR, coordinadores de la traducción. Guía de tratamiento del tabaquismo. Sociedad Española de Neumología y Cirugía Torácica, SEPAR; 2010.
29. Barrueco Ferrero M., Jiménez Ruiz C.A., Palomo A., Torecilla M., Romero P.J., Riesco J.A. Veracidad de las respuestas de los fumadores en las consultas de deshabituación tabáquica sobre su abstinencia. Arch Bronconeumol 2005, 41:135-140.
30. Muhammad-Kah R., Liang Q., Frost-Pineda K., Mendes P.E., Roethig H.J., Sarkar M. Factors affecting exposure to nicotine and carbon monoxide in adult cigarette smokers. Regul Toxicol Pharmacol 2011, 61:129-136.
31. Perez Trullén A., Lázaro Sierra J., Clemente Jiménez L., Herrero Labarga I., Pau Pubil M., Cascán Herreros P. Marcadores biológicos y funcionales de susceptibilidad, exposición y lesión por el consumo del tabaco. Tratado de tabaquismo 2011, 323-340. Aula Médica, Madrid. 3.a ed. C.A. Jiménez Ruiz, K.O. Fagerström (Eds.).
32. Hall K., Gibbie T., Lubman D.I. Motivational interviewing techniques - facilitating behaviour change in the general practice setting. Aust Fam Physician 2012, 41:660-667.
33. Arrol B., Khin N., Kerse N. Screening for depression in primary care with two verbally asked questions: Cross-sectional study. BMJ 2003, 327:1144-1146.
34. Medici T.C., Unger S., Ruegger M. Smoking pattern of smokers with and without tobacco-related lung diseases. Amer Rev Resp Dis 1985, 131:385-388.
35. Jimenez Ruiz C.A. Psychological and behavioural interventions for smoking cessation. Smoking Cessation 2008, 42:61-74. European Respiratory Monograph.
36. Fagerström K.O. Assessment of the patient. Smoking Cessation 2008, 42:44-50. European Respiratory Monograph.
37. Schünemann H.J., Jaeschke R., Cook D.J., Bria W.F., El-Solh A.A., Ernst A., et al. An official ATS statement: Grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006, 174:605-614.
38. Bize R, Burnand B, Mueller Y, Walther MR, Cornuz J. Evaluación del riesgo biomédico como ayuda para el abandono del hábito de fumar (Revisión Cochrane traducida). En: Biblioteca Cochrane Plus 2009, Número 3. Oxford: Update Software Ltd. Disponible en: (Traducida de The Cochrane Library, 2009 Issue 2 Art no. CD004705. Chichester, UK: John Wiley & Sons, Ltd.). http://www.update-software.com/.
39. Müller M., Kögler H., Glaab T., Welte T. Use of a lung function screening device for identifying patients at risk for COPD in general practice. Pneumologie 2012, 66:645-649.
40. Pelegrino N.R., Tanni S.E., Amaral R.A., Angeleli A.Y., Correa C., Godoy I. Effects of active smoking on airway and systemic inflammation profiles in patients with chronic obstructive pulmonary disease. Am J Med Sci 2012 Aug 7, 10.1097/MAJ.0b013e31825f32a7.
41. Jiménez Ruiz C.A., Riesco Miranda J.A., Ramos Pinedo A., Barrueco Ferrero M., Solano Reina S., de Granda Orive J.I., et al. Recomendaciones para el tratamiento farmacológico del tabaquismo. Propuesta de financiación. Arch Bronconeumol 2008, 44:213-219.
42. Tønnesen P., Carrozzi L., Fagerström K.O., Gratziou C., Jimenez-Ruiz C., Nardini S., et al. Smoking cessation in patients with respiratory diseases: A hig priority, integral component of therapy. Eur Respir J 2007, 29:390-417.
43. Shiffman S., Fergusson S.G. Nicotine patch therapy prior to quitting smoking: A meta-analysis. Addiction 2008, 103:557-563.
44. Tonstad S., Tonnesen P., Hajek P., Williams K., Billing C., Reeves K., et al. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 2006, 296:64-71.
45. Ebbert J., Croghan I.T., Sood A., Schroeder D.R., Hays J.T., Hurt R.D. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nic Tob Res 2009, 11:234-239.
46. Ebbert J., Burke M.V., Hays T., Hurt R. Combination treatment with varenicline and nicotine replacement therapy. Nic Tob Res 2009, 11:572-576.
47. Hajek P., McRobbie H., Myers K., Stapleton J., Al-Rehan D. Use of varenicline for 4 weeks before quitting smoking. Arch Intern Med 2011, 171:770-777.
48. Lindson-Hawley N., Aveyard P., Hughes J.R. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2012 Nov 14, 11. CD008033. 10.1002/14651858.CD008033.pub3.
49. Moore D., Aveyard P., Connock M., Wang D., Fry-Smith A., Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: Systematic review and meta-analysis. BMJ 2009, 338:b1024. 10.1136/bmj.b1024.
50. Fiore M.C., Baker T.B. Clinical practice. Treating smokers in the health care setting. N Engl J Med 2011, 365:1222-1231.
51. Hughes J., Rennard S., Fingar J., Talbot S.K., Callas P.W., Fagerstrom K.O. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: A randomized placebo-controlled trial. Nic Tob Res 2011, 13:955-964.